Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03553823 · ClinicalTrials.gov registry record · Phase 2
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT03553823 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT03553823, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The aim of this study was to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic plaques that remain active despite treatment with the non-selective IL-23 inhibitor ustekinumab (blocker of p40 subunit, shared by IL-12 and IL 23).
Interventions
- PROCEDURE Skin biopsies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2020-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03553823
The ClinicalTrials.gov registry entry for NCT03553823 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Skin biopsies is the first listed.
NCT03553823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03553823 about?
NCT03553823 is a clinical study titled "Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab". The aim of this study was to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic plaques that remain active despite treatment with the non-selective IL-23 in...
What is the current status of trial NCT03553823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-01-14. Estimated completion is 2020-01-28.
What interventions are being tested in trial NCT03553823?
The interventions under investigation include: Skin biopsies (PROCEDURE).
Who is sponsoring clinical trial NCT03553823?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.